Kinaxo Inks Screening Deal with Daiichi Sankyo | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Kinaxo Biotechnologies today said that it has entered into a long-term cancer drug screening pact with Japanese pharmaceutical firm Daiichi Sankyo.

Martinsried, Germany-based Kinaxo said that Daiichi Sankyo will use its chemical proteomics technologies Cellular Target Profiling and KinAffinity, as well as its phosphoproteomics technology PhosphoScout in various research programs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.